- 7.13.2026
- News
Massachusetts House Advances Psychedelic Therapy Pilot Program
Massachusetts lawmakers advanced legislation to create a five-year psychedelic-assisted therapy pilot program, with VETS playing a key advocacy role by supporting the measure and celebrating it as a major step toward expanding safe, regulated access to psychedelic-assisted therapy for veterans and others with serious mental health conditions.
- 7.8.2026
- News
Utahns are traveling abroad for ibogaine, while experts voice both optimism and caution around the emerging drug.
The article spotlights VETS Foundational Healing Grant recipient Kyle Bingham, a former Green Beret who shares how ibogaine treatment and ongoing integration support helped him better manage PTSD while underscoring the promise and complexities of psychedelic-assisted therapy.
- 7.2.2026
- News
Why Are Republicans Suddenly for Ibogaine?
The article highlights VETS’ leadership in expanding access to psychedelic-assisted therapy, showcasing how the organization funds veterans’ ibogaine treatment abroad, provides critical integration support, and advances state and federal policy efforts to accelerate research and establish safe, regulated clinical access in the United States.
North Carolina veteran describes ibogaine as a turning point in life after war
The story highlights VETS Foundational Healing Grant recipient Chris Boardman, a retired Army veteran who says ibogaine treatment in Mexico, made possible through VETS, helped him confront the effects of PTSD and traumatic brain injury, overcome substance use, and find a renewed sense of peace after years of struggle.
- 6.30.2026
- News
Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant Psychedelic Legislation of 2026
Written by VETS Legislative Director Logan Davidson, this article highlights Utah’s landmark passage of HB 390 as one of 2026’s most significant yet underrecognized legislative victories, establishing the nation’s first state-funded clinical research authorization for 5-MeO-DMT and advancing rigorous, veteran-focused psychedelic-assisted therapy research.